Skip to content
DataLookout
Menu

ROMISTERNCT07700238

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP)

StatusRecruiting
PhasePhase 3
SponsorAmgen
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 32 words
    • Trial sites expanded: 3 → 21 locations
    • Start date changed from estimate of Aug 21, 2026 to Oct 15, 2026
    • Study title expanded, about 2 words
  2. Notable Recruitment opened Show 4 more changesShow less
    • Start date: Jul 20, 2026 to Aug 21, 2026
    • Eligibility criteria expanded, about 15 words
    • Trial sites expanded: 0 → 3 locations
    • Study completion pushed from Sep 14, 2029 to Oct 14, 2029
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage of Participants With a Durable Platelet Response (DPR)
Timeframe: 8 weeks

Secondary (9)

Time to Next Treatment (TTNT)
Cumulative Exposure to Corticosteroids
Change From Baseline in ITP Patient Assessment Questionnaire (ITP-PAQ)
Change in Summary Scores and Visual Analogue Scale (VAS) Scores per EuroQol 5-Dimension 5-Level (EQ 5D-5L)
Incidence of Hospitalization and Rescue Medication in Part 1
Show 4 moreShow less
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Interest (EOI), and Fatal TEAEs
Percentage of Participants With Clinically Significant Bleeding Events in the Immune Thrombocytopenia-specific Bleeding Assessment Tool (ITP-BAT)
Serum Trough Concentration (Ctrough) of Romiplostim
Number of Participants With Anti-Romiplostim Antibodies and Anti-Thrombopoietin (TPO) Antibodies

Arms and interventions

Romiplostim + Predniso(lo)neExperimental

Participants will receive romiplostim administered subcutaneously (SC) in combination with predniso(lo)ne administered orally during Part 1 of the study. Participants who complete Part 1 of the study will enter Part 2 and continue participation for study assessments.

Predniso(lo)neActive comparator

Participants will receive predniso(lo)ne administered orally during Part 1 of the study. Participants who complete Part 1 of the study will enter Part 2 and continue participation for study assessments.

Drugs: Romiplostim, Predniso(lo)ne

Sites

21 sites in 5 countries

Turkey (Türkiye) 5, Germany 4, Hungary 4, Spain 4, United States 4